Regeneron Upgraded To Overweight From Neutral At Piper Jaffray

Piper Jaffray analyst Edward Tenthoff upgraded Regeneron Pharmaceuticals to Overweight saying that while Eylea growth is slowing, new approvals are coming.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.